18th Edition of International Conference and Exhibition on

Pharmaceutics and Novel Drug Delivery Systems

Theme: Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems

Event Date & Time

Event Location

Warsaw, Poland

18 years of lifescience communication

Previous Conference Performers / Professionals From Around The Globe

Tracks & Key Topics

Pharmaceutics 2019

Past Conference Report

Thanks for participating in Pharmaceutics 2018

Pharmaceutics 2018

The 17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems was held on October 04-06, 2018 in Moscow, Russia with the presence of professional researchers, business delegates, scientists involved in the development of high-quality education & research in all aspects. Please check the website: Pharmaceutics 2018 Conference Photographs

Pharmaceutics 2018 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various topics related to the fields of Pharmaceutics and Drug Delivery Systems. The highly exalted conference hosted by EuroSciCon was marked with the attendance of renowned and brilliant researchers, business delegates and talented student communities representing more than 30 countries around the world. The conference has tried grounding every aspect related to Pharma Industry, covering all the possible research areas.

The conference aimed a parallel rail with theme “Challenges Innovations and Advances in Novel Drug Delivery Systems”. The meeting engrossed a vicinity of cognizant discussions on Targeted Drug Delivery System: Advances and Approaches, Nanotechnology in Drug Delivery, Drug Discovery and Development Obstacles, Drug Delivery through BBB, Innovative Drug Delivery Technologies, Pharmacokinetic and Pharmacodynamic Studies, Smart Materials for Drug Delivery , Protein, Peptide and Gene Drug Delivery, Recent Advances in Drug Delivery Systems, Drug Delivery Vehicles , Nanoparticles: Innovations and Trends. The three days event implanted a firm relation of upcoming strategies in the field of Pharma Industry with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.

We are thankful to all our speakers for encouraging and supporting us to conduct the conference and catapulting the same to pinnacle of success.

We would like to thank our Organizing Committee Members Dr. Vladimir P Torchilin, Northeastern University, USA  , Dr. Sergey Suchkov, Sechenov University, Russia for their support throughout the conference without your cooperation which lead us to the grand success of Pharmaceutics 2018 Conference

The Organizing Committee would like to thank the moderator: Dr. Ayse Nur Oktay, Gazi University, Turkey and Olga Mikhailovna Mulina, N D Zelinsky Institute of Organic Chemistry-RAS, Russia for their valuable contribution which resulted in smooth functioning of the conference.

 We would also like to thank our Poster judge Dr. Sergey Suchkov, Sechenov University, Russia for the evaluation of Poster Presentations.

 The meeting was embarked with an opening ceremony followed by Keynote Sessions and followed by series of lectures delivered by Honorable Guests and members of the Keynote forum. The highlights of the meeting were the eponymous lectures, delivered by:

 Vladimir P Torchilin, Northeastern University, USA

Alexander O Terentev, N D Zelinsky Institute of Organic Chemistry-RAS, Russia

Muna Abubaker, University of Salford, UK

Essam Ghanem, Celyad Biopharmaceutical, Belgium

Dushkin Alexandr Valerevich, Institute of Solid State Chemistry SB RAS, Russia

Alyabyeva Zhanna Yurievna, Pirogov Russian National Research Medical University, Russia

Olga V Dementeva, Frumkin Institute of Physical Chemistry and Electrochemistry of RAS, Russia

Ruey-an Doong, National Chiao Tung University, Taiwan

Jayvadan K Patel, Sankalchand Patel University, India

Tamara Zwain, University of Central Lancashire, UK

Yong-Xi Li, Medpace Bioanalytical Laboratories, USA

Sergey Suchkov, Sechenov University, Russia

Dimosthenis Mavrilas, University of Patras, Greece

Ayse Nur Oktay, Gazi University, Turkey

Ilya Yakavets, Belarusian State University, Belarus

Ruth Belostotsky, Shaare Zedek Medical Center, Israel

Suneel I Majagi, Gadag Institute of Medical Sciences, India

Zahid Iqbal, Isra University, Pakistan

Fatemeh Farjadian, Shiraz University of Medical Sciences, Iran

Anika Staack, MEDICE, Germany

Poster competition also held for the young scientists and the best poster presenter has been awarded by the Dr. Sergey Suchkov, Sechenov University, Russia.

Pharmaceutics 2018 had an effective networking session which enables the professionals and scientists to get involved & enlightened them in all perspectives. We also like to thank all the delegate professionals from various countries like India, Nepal who attended the conference shared their industrials experiences in networking sessions. Please check the website: Pharmaceutics 2018 Conference Photographs to visualize the conference photographs



EuroSciCon is prerogative to thank the Organizing Committee Members, Keynote speakers and Chairs on transcribing the plenary sessions in a diversified and variegate manner to make this conference an enviable artifact.

Pharmaceutics 2018 would not have reached the pinnacle if not with the support of International, multi-professional steering committee and coordination of International Journal of Drug Development and Research, American Journal of Drug Delivery and Therapeutics and Journal of Pharmacy and Pharmaceutical Research.

With the grand success Pharmaceutics 2018, we are glad to announce our next upcoming conference “18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems ” which is going to be held in Warsaw, Poland during October 14-15, 2019 on the theme "Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems "  

 Bookmark your dates…

Hoping to meet you again coming year at Warsaw!!!



About Conference

EuroSciCon invites participants from all over the world to attend ''18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems” during October 14-15,2019 at Warsaw, Poland which includes prompt keynote presentations, Oral talks (Speaker Forum and Young Research Forum), Poster presentations, Symposium, Workshops and Exhibitions.

Pharmaceutics 2019 spreads an extensive range of critically important sessions from basic research to recent innovations. The theme: “Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems” is designed for professionals at all levels and career phases of the Pharma industry, who want to improve their understanding of what will drive and shape the future of the market. 

What’s New

Pharmaceutics 2019 offers a best stage with its proficient legitimate program to the social event of individuals which consolidates instinctive board discoursed, keynote addresses, all-hands gatherings and notice sessions on the topics Clinical Trails, Drug Discovery, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, Drug transport,Gene Therapy, Therapeutic Biological Products, BABE, Biosimilars, , new coherent approaches to managing overall managerial measures, Biopharmaceutical Companies and Market Analysis, The get-together invites delegates from Biopharma associations, Pharmacists, Academicians, Clinicians, Researchers, Health mind specialists, understudies, business operators and Young authorities over the globe giving a predominant stage, interconnecting the latest research, creative enhancements in the field and furthermore helpful viewpoints.

Target Audience

Nobel laureates in Health Care and Medicine


Pharmaceutical companies

Pharmacovigilance Companies

Clinical Laboratories

Supply Chain companies

Manufacturing Companies

Pharmaceutical Industrial Giants

Biotechnology Companies

Research Institutes and members

Regulatory Operations and Affairs Outsourcing experts


Pharmacy Students


Business Entrepreneurs



Toxicology and Pharmacology Students

Pharmacy Societies and the people Associated

Pathology Professionals

Genetic Professionals

Bio-informatics Professionals

Training Institutes

Nursing Professionals

Why to attend our Conference:

Euroscicon Conferences promotes the positive contributions of Pharma industry. Highlighting the material’s beneficial properties and its positive contributions to society throughout its life cycle providing society with educational information to help raise awareness and correct misconceptions. Discover how advances in the sector are impacting both large and small molecule drugs. Explore new routes to improve bioavailability. Liaising with European and national institutions in policy matters to secure decisions based on accurate information. Communicating chemicals and its related contribution to sustainable development, innovation and quality of life initiating in depth studies and sharing experiences. Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set. Discover the latest innovations in drug delivery devices. Get to know why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions. Share experiences, insights and strategies in interactive peer-to peer round tables. Discover how scientific formulation advancements are being implemented in practice.

Opportunities for Conference Attendees

For Researchers &Faculty:

  • Speaker Presentations
  • Poster Display
  • Symposium hosting
  • Workshop organizing

For Universities, Associations & Societies:

  • Association Partnering
  • Collaboration proposals
  • Academic Partnering
  • Group Participation

For Students & Research Scholars:

  • Poster Competition (Winner will get Best Poster Award)
  • Young Researcher Forum (YRF Award to the best presenter)
  • Student Attendee
  • Group registrations

For Business Delegates:

  • Speaker Presentations
  • Symposium hosting
  • Book Launch event
  • Networking opportunities
  • Audience participation

For Companies:

  • Exhibitor and Vendor booths
  • Sponsorships opportunities
  • Product launch
  • Workshop organizing
  • Scientific Partnering
  • Marketing and Networking with clients

Top Pharmacy companies around the Globe:

Johnson & Johnson




GSK (GlaxoSmithKline)


Gilead Sciences

Major Pharma Associations around the Globe:

International Pharmaceutical Federation (FIP)

International Pharmaceutical Students' Federation (IPSF)

European Association of Employed Community Pharmacists in Europe (EPhEU)

Pharmaceutical Group of the European Union (PGEU)

National Pharmacy Association

Pharmaceutical Society of Northern Ireland

Royal Pharmaceutical Society (RPS)



Track 1: Nanotechnology in Drug Delivery

Nanotechnology became the driving force behind various evolutionary and revolutionary changes in the scientific field.  Nanotechnology drug delivery enhanced the efficacy of available medicaments and enabled to create entirely new medical products. Nanotechnology has opened the door to new approaches to stimulate the reconstruction of complex tissue structures. Nanoparticles are used to deliver the drug to the specific diseased cell where particles attract to the diseased cell and provide treatment. By this unique technique, we can minimize the damage of healthy cells in the body.

Nanotechnology-dependent detectors e.g. nanowires, nanotubes, nanoparticles, cantilevers, and nano arrays consume low sample and enhance fast detection of disease. Target based Nano probes (e.g. magnetic nanoparticles, quantum dots, and carbon nanotubes) provide a faster, less invasive, and more accurate way for early diagnose of diseases. Reporting in vivo efficacy of therapeutics and helping surgeons to locate tumors are other opportunities of nanotechnology.

Some nanotechnology-based drugs that are commercially available are- Abraxane, approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. Doxil was approved by the FDA for the treatment of ovarian cancer.

The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023. 

Track 2: Targeted drug delivery: Advances and Approaches

Targeted drug delivery is a kind of smart drug delivery, a method of delivering medication to a patient in a manner that increases the concentration only in particular part of the body. The goal of a targeted drug delivery system is to prolong, localize and have a protected drug interaction with the diseased tissue. The advantages of the targeted drug delivery are 1. reduction in the frequency of the dosages taken by the patient 2. have a more uniform effect of the drug, 3.reduction of drug side-effects 4. reduce fluctuation in circulating drug levels 5.maintain the required plasma and tissue drug levels in the body. In chemotherapy only a small portion of the medication reaches the affected organ and roughly 99% of the administered drug does not reach the tumor site.

While designing a targeted drug delivery, the following criteria must be taken into consideration: the drug properties, the route of drug delivery, the targeted site, disease and the side effects of drug. There are two kinds of targeted drug delivery: active targeted drug delivery, such as antibody medications, and passive targeted drug delivery, such as the enhanced permeability and retention effect.

Track 3: Innovative Drug delivery technologies

Drug delivery is the action of administering a pharmaceutical drug into the body for a therapeutic effect through various routes. Drug delivery technologies modify drug release profiles, pharmacokinetic parameters for the benefit of improving product efficacy and safety, as well as patient convenience and compliance. Conventional routes cannot deliver compounds such as proteins, antibodies, vaccine and gene based drugs because these routes are susceptible to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently due to large molecular size and charge issues.

Technologies include digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, fiber-based technology for implantable devices, targeted penetration matrix technology for non-invasive delivery and location-specific nano devices for chemotherapy delivery. Many innovative technologies for effective drug delivery have been developed, including implants, nanotechnology, cell and peptide encapsulation, micro fabrication, chemical modification.

Biotechnology advances are leading to develop medications that can target diseases more effectively and precisely. If a drug is more targeted, the chance of triggering drug resistance is lower, a cautionary concern surrounding the use of broad-spectrum antibiotics.

Nanotechnology delivers drugs to targeted cells using nanoparticles. The overall drug consumption and side-effects are lowered significantly by depositing the active drug in the particular site and preventing administration of booster doses. Nanotechnology based devices are less invasive, can be safely implanted inside the body and biochemical reaction times are much shorter.

Track 4: Recent Advances in Drug Delivery

The goal of drug delivery systems is to deliver medications to specific target parts of the body through a medium that can control the therapy’s administration. To achieve this goal, researchers are turning to advances in the worlds of micro- and nanotechnology.

The recent advances in the peptide and protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute a current hotspot in medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes, and are considered more efficient and safe and providing new avenues for research and applications in life sciences.

Biologics can be re-engineered for BBB transport with the use of molecular Trojan horse technology.

Needle-free drug delivery systems are novel ways to introduce various medicines to patients. PowderJect Pharmaceuticals one of the first companies to develop a needle-free technology for injecting powdered drugs into the skin. Needle free devices can take the form of power sprays, edible products, inhalers, and skin patches

Transdermal patches are user-friendly, convenient, painless and offer improved patient compliance.

Nano drug delivery systems such dendrimers, fullerence, nano pores, nanotubes, nano shells, quantum dots, , nanovaccines, revolutionized drug delivery systems. Thus nanomaterial can be used for strategic development of new drug delivery systems and reformulate existing.

Anti-cancer drugs such as loperamide and doxorubicin bound to nanomaterial have been shown to cross the blood-brain barrier.

Track 5: Nanoparticles: Innovations and Trends

Nanoparticles are generally less than 100 nm in dimension and consist of different biodegradable materials such as natural or synthetic polymers, lipids, or metals. Nanoparticles are taken up by cells more efficiently than larger micromolecules. Nanoparticles have high surface area to volume ratio thus allowing many functional groups for attachement. Additionally, the small size of nanoparticles allows them to accumulate at tumor sites.     

Nano particles can (1) enhance the therapeutic efficacy and minimize adverse reactions associated with available drugs; (2) enable new classes of therapeutics; and (3) encourage the re-investigation of pharmaceutically suboptimal but biologically active new molecular entities that were previously considered undevelopable.

Nanoparticles are used in targeted drug delivery to improve the uptake of poorly soluble drugs. Nano particles with different compositions and biological properties have been extensively investigated for drug and gene delivery application.

According to BCC Research the global market for nanoparticles in the life science forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.

Track 6: Drug Delivery: Facing Challenges

Innovative, non-invasive delivery include drivers like improvement of patient acceptability and compliance ,improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzyme degradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the gastrointestinal (GI) tract surfaces make oral administration a non-viable delivery method. Conventionally, many drugs such as proteins are administered parenterally since oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.

Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity,  cytotoxicity of nanoparticles are  main concern of future research.

Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry, including pharmaceuticals and healthcare. The development of new drugs necessitates the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human biology, diseases and medical treatments are opening new opportunities in the pharmaceutical industry. A drug delivery system is an important area where the need for better technologies for drug administration or delivery is in demand

Track 7: Drug delivery through BBB

One of the biggest challenges in the drug development for central nervous system (CNS) disorders is achieving significant blood–brain barrier (BBB) penetration.

Several drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The problems associated with the blood–brain barrier are1. The drug produced allows only a small amount to pass through the barrier 2. Binding to other proteins in the body renders the drug ineffective or pass through the barrier with the adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed and accounted to deliver effective drugs to the brain.

Nano biotechnology-based delivery methods provide the best approach to deliver drugs. Several developed strategies, enhance the capacity of drug molecules to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.

By 2019, compounds using BBB technology in the clinical development would reach approximately eight. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.

Track 8: Novel Drug Delivery Systems

It is defined as the method by which a drug is delivered can have a significant effect on its efficacy i.e. the drug become more efficacious in order to minimize drug degradation, drug adverse effect, and in order to increase the drug bioavailability to produce better therapeutic effect. NDDS covers various aspects like pharmacokinetics & pharmacodynamics, non-specific toxicity, immunogenicity, bio recognition, and drug’s efficacy based on preferable approaches that include polymer science, pharmaceutical technology, dispensing pharmacy, packaging technology, bio conjugate chemistry, and molecular biology. NDDS based on two mechanism i.e. physical and biochemical

Track 9: Drug delivery vehicles

A drug carrier improves the selectivity, effectiveness, and safety of drug administration. Drug carriers are primarily used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time (typically diffusion) or by triggered release at the drug's target by stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers improve the bioavailability of poorly water soluble or membrane permeable drugs.

An ideal drug delivery vehicle must be non-toxic, biocompatible, non-immunogenic, biodegradable and must avoid recognition by the host's defense mechanisms. Different methods of drug attachment to the carrier include adsorption, integration into the bulk structure, encapsulation, and covalent bonding. As many drug delivery carriers are involved in delivery of the drug, the conference can be re-named as Drug Delivery carrier conference

Track 10: Protein, Peptide and Gene Drug Delivery

Peptides and proteins have great potential as drug delivery. Compared with the small size drugs, peptides and proteins can be highly selective as they have multiple points of contact with their target. Increased selectivity also result in decreased side effects and toxicity. Peptides can be designed to target a broad range of molecules and provide opportunities in oncology, immunology, infectious disease and endocrinology. The market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market .At present there are over 100 approved peptide-based drugs in the market. The pharmaceutical scientists have approaches to develop the protein and peptide delivery formulations by noninvasive routes.

Gene therapy is defined as incorporation of genetic material i.e, DNA or RNA, in the cellular gene regulation system, either to correct the expression of a malfunctioning gene or to modulate the cellular functions. Nanotechnology advancements have given rise to the development of nanoparticle-DNA delivery systems. Gene delivery is an integral part of genome evolution. Gene delivery utilizes non-immunogenic vectors capable of cell specificity that can deliver an adequate amount of transgene expression to cause the desired effect. Advances in gene therapy have enabled a variety of new methods and gene targets to be identified for possible applications. Gene delivery has been utilized to generate a hybrid biosynthetic vector to deliver a possible vaccine.

Track 11: Pharmacokinetic and Pharmacodynamic Studies

Pharmacokinetics describes how the medicament gets influenced after administration, followed by absorption, distribution, metabolism mechanisms and excretion of the drug substance. Pharmacokinetic knowledge assist prescribers to adjust dosage more accurately and precisely. Clinical kinetics is defined as the applications of pharmacokinetic principles in the safe and adequate management of individual patient. Toxic pharmacokinetics is defined as the applications of pharmacokinetic principles to the design, behaviour and interpretation of drug safety evaluation studies.

Pharmacodynamics describes biochemical, physiological, and molecular effects of drugs on the body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical reactions. The pharmacologic response depends on the drug binding to its target. Pharmacodynamics is defined as the relationship between drug concentration at the site of action and the resulting effect. The effect of a drug present at the site of action is measured by drug-receptor binding.

Track 12: Drug Discovery, NCEs and Drug Development

Drug discovery is the process through which potential new medicines are recognized and comprises an extensive range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies is a key characteristic in drug discovery for efficacy and safety assessment, in the particular for the translation from the non-clinical to  clinical field and process of drug discovery include  the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy whereas modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability. The "final product" of drug discovery is a patent on the potential drug.

FDA provides scientific and regulatory advice needed to bring new therapies to market. In 2018 FDA has approved 43 new drugs which are presently in the market. Each year, CDER approves series of new drugs and biological products. The availability of new drugs and biological products often means new treatment options for patients and advances in health care. Some of these products are often innovative new products that never before have been used in clinical practice. A new chemical entity (NCE) is a drug that contains no active moiety that has been approved by the FDA in any other application submitted under the Federal Food, Drug, and Cosmetic Act

Track 13: Pharmacovigilance, Risk Management and Drug safety

Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates. Pharmacovigilance legislation gives an outlook on the rules and laws to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of pharmacovigilance system is very crucial to maintain the safety data, Detection and Evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines

Prescription Safety is the pharmacological science ensuring security and related to the aggregation, area, assessment, watching, and repugnance of hostile side effects with pharmacological movement of pharmaceutical things. As demonstrated by US FDA a drug is seen as protected by looking, its collecting technique and delayed consequences of animal testing and clinical preliminaries. In this track, we look at Drug security and its applications in various fields, for instance, Software, Training et cetera.

Track 14: Smart Materials for Drug Delivery

Materials are called “smart” when these materials have the ability to respond to stimuli and have high potential in novel drug delivery systems. The delivery of drugs to specific locations in the human body using smart materials has been approaching the forefront place in research for the past few decades. Materials for delivering drugs must design drug carriers that do not interact non-specifically within the body.

Polymers have played an important role in the advancement of drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods and release of both hydrophilic and hydrophobic drugs. The greatest advantage of polymers  is their ability to chemical modification, resulting in defined chemical composition, customized surface functionality and the potential for defined three-dimensional structures. Several polymers widely used in clinical therapies are synthetic polymers and natural polymers.

Nano materials are used in controlled drug delivery. Drug-delivery systems can be synthesized with controlled composition, shape, size and morphology. Nanoparticles surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake.

Natural gums are one of the major areas for applications in the drug delivery system because of their wide availability, inexpensiveness.

Track 15: Herbal Novel Drug Delivery

Novel drug delivery system addresses the limitations of the traditional drug delivery systems. We have a vast knowledge of Ayurveda and the drug delivery system used for administering the herbal medicine to the patient is traditional. So it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat serious diseases.

Reasons for using herbal medicines are 1.  Growing concern over the reliance and safety of drugs 2.Failure of modern medicine to treat most common health conditions   3. Natural medicines are producing better results without side effects.


Novel herbal formulations like polymeric herbal Nano-carriers, phytosomes, herbosomes, pro-niosomes, Nano emulsions, microsphere, transferosomes, implants and ethosomes has been reported using bioactive plant extracts. Advantages include Solubility, bioavailability enhancements, reduced toxicity, improved pharmacological activity, sustained delivery, and protection from physical and chemical degradation. Many formulations are produced from various herbal drugs such as curcumin, quercetin, silybin, bilobalide, marsupsin, andrographolide.

According to WHO because of poverty and lack of access to modern medicine as well as self-belief, about 65-80% of the world's population living in developing and developed countries depends on plants for primary health.

Track 16: Pre-formulation & Formulation Aspects

Pre-formulation studies are an essential aspect for various phases of clinical trials. Pre- formulation studies act as the preliminary step as well as the scientific foundation for formulation design and development. These studies provide guidance in selection of drug, excipients, to determine chemical composition, physical pattern and assist in adjustment of pharmacokinetic profiles. Improving public safety measures and intensifying product quality are the other characteristics.

The main purpose of pre-formulation studies is to enhance compatibility with the other ingredients and develop elegant, stable, potent and safe dosage form. Physico-chemical parameters, drug solubility studies, partition coefficient, dissolution kinetics, polymorphism and stability profiles play a significant role in pre-formulation studies. These studies furnish the information regarding the degradation process, toxic effects and adverse conditions. So Pre-formulation is an interdisciplinary basis in drug development.

Formulation is defined as the method in which different chemical substances including the main active ingredient are compounded to produce a final dosage form. Developed formulations should be stable, safe and acceptable to the patient.

Track 17: Novel Vaccine Delivery Systems

Vaccine is a material that induces an immunologically mediated resistance to a disease but not necessarily an infection. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Vaccines though exceptionally selective and specific in reacting with antibodies often fail to show reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. These vaccines require boosting with agents called adjuvants in order to induce an effective immunity. Adjuvants potentiate the immunostimulatory property of the antigen and are non-immunogenic, nontoxic, and biodegradable in nature.

Conventional immunization regimen involves prime doses and booster doses. Immunization failed as patients neglect the booster doses. These reasons necessitated the development of new generation of prophylactic and therapeutic vaccines to promote effective immunization. Vaccines allow for the incorporation of doses of antigens so that booster doses are no longer necessary as antigens are released slowly in a controlled manner. Attempts are being made to deliver vaccines through carriers as they control the spatial and temporal presentation of antigens to immune system thus leading to their sustained release and accurate targeting. Carrier systems such as liposomes, microspheres, nanoparticles, dendrimers, micellar systems, ISCOMs, plant-derived viruses are being investigated and developed as vaccine delivery systems

Track 18: Novel Drug Delivery: 2D & 3D Printing applications

Activities have been increased regarding the development and research on various printing techniques in fabrication of dosage forms. These technologies offer flexibility in manufacturing, potentially pave the way for personalized dosing and tailor-made dosage forms.

Drug delivery from 3-dimensional (3D) structures is a rapidly growing area of research. 3DP can fabricate solid dosage forms with variable densities and diffusivities, complex internal geometries, multiple drugs and excipients.

3DP uses computer aided technology and programme to transform 3D computer aided designs (CAD) into life-changing products. These design more effective and patient-friendly pharmaceutical products as well as bio-inspired medical devices. Levetiracetam (SPRITAM®) tablet a pharmaceutical product is developed by using 3DP technology.

3DP offers advantages like (a) high production rates due to its fast operating systems, (b) ability to achieve high drug-loading with much desired precision and accuracy especially for potent drugs that are applied in small doses, (c) reduction of material wastage which can save in the cost of production and (d) amenability to broad types of pharmaceutical active ingredients including poorly water-soluble, peptides and proteins, as well as drug with narrow therapeutic windows.

3D structures can be printed on a variety of surfaces with characteristic permeability, porosity, hydrophobicity/hydrophilicity and surface energy. Scientists in collaboration with CAD designers have produced innovative medical devices ranging from pharmaceutical tablets to surgical transplants of the human face and skull, spinal implants, prosthetics, human organs and other biomaterials.

Track 19: Clinical Research and Clinical Trials

Clinical trial is a part of clinical research that follows a regulated protocol, or plan of action. Clinical trials are primarily performed to get data on safety and efficacy of the new developed drug, this data is mandatory for further approval of the drug and to bring it into the market. Clinical trials, especially those taking a gander at new medications, regularly begin after effective creature examines. The most encouraging medicines at that point move into clinical trials.

There are four classifications of clinical trials. The fourth happens after the FDA has cleared a specific medication or treatment and keeps on following the security of the treatment.  A clinical review includes inquire about utilizing human volunteers (likewise called members) that is proposed to add to therapeutic learning. Test potential medicines in human volunteers to see whether they ought to be endorsed for more extensive use in the all-inclusive community

The global clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% until 2025.

The interventional study design is the most prominent method of conducting clinical trials across with globe. According to statistics provided by the U.S. FDA, over 126,000 trials are currently being conducted by means of this method. Based on indication, the oncology segment is anticipated to witness the fastest growth.

Track 20: Pharmaceutical Regulatory affairs and Intellectual Property Rights

Regulatory affairs is a comparatively new profession which developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals , veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines. Regulatory Affairs is involved in the development of new medicinal products from early on, by integrating regulatory principles and by preparing and submitting the relevant regulatory dossiers to health authorities. Regulatory Affairs is actively involved in every stage of development of a new medicine and in the post-marketing activities with authorized medicinal products. The Regulatory Affairs department is an important part of the organizational structure of pharmaceutical industry. Internally it liaises at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities.

Track 21: Pharmaceutical Manufacturing and Scale Up Process

The biopharmaceutical sector in US enjoys 17% of all domestic R&D funded by the country and in return gave $2.5 trillion cumulative addition in economic output in 2016. Companies engaged in the brand name pharmaceutical manufacturing have grappled in recent years owing to the largest waves of drug patent expirations in history. As a consequence enabling low-price generic drugs to inundate the market.  Many brand name pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers, cutting into revenue growth. Until the next the five years till 2022, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs.

Recently, process engineers have shown inclination to single-use, modular and continuous manufacturing technologies to improve efficiency and minimize scale-up and technology transfer challenges in the pharmaceutical industry. Lot of these innovations are driven by updates instigated by the FDA. The changes are inevitable; especially in the already aging biopharmaceutical sector of the industry, where original processes are often overly complex, and are characterized by inefficiency, and occasionally, inherent unpredictability.

Track 22: Pharmaceutical Chemistry

Pharmaceutical chemistry is a branch at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various biological specialties, where they participate in the design of drugs, chemical synthesis and development for the market, or bioactive molecules (drugs). In particular, pharmaceutical chemistry in its most common guideline focusing on small molecules / organic entities encompasses synthetic organic chemistry and aspects of natural product chemistry and computational chemistry in close combination with chemical biology, enzymology and structural biology, together with the goal of discovery and drug development of new different therapeutic agents. Speaking in practical terms, it involves chemical aspects of identification and, subsequently, a systematic and exhaustive synthetic alteration of new chemical entities to make them appropriate for therapeutic use. It includes synthetic and computational aspects of the study of drugs and agents existing in the development in relation to their biological activities (activities and biological properties), that is, the understanding of their structure-activity relationships (SAR). Pharmaceutical chemistry focuses on the quality aspects of medicines and aims to ensure the adequacy of the purposes of the medicines.

Track 23: Pharmaceutical Analysis

Chromatography and MS are extensively used in the formulation development stage of generic drug products. The ICH Q3B guidelines address the reporting threshold, identification threshold, and qualification threshold for impurities in the drug product.  Chromatography (LC) and Gas Chromatography (GC) are extensively used to analyze stable compounds. However, for labile compounds require derivatization prior to LC or GC analysis. For certain selected analyses, Liquid Chromatography- Ultraviolet Detection (LC-UVD) and Gas Chromatography-Flame Ionization Detection (GC-FID) techniques may be deemed suitable. However, Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are usually the techniques of choice when higher specificity and sensitivity are required. Gas Chromatography-Electron Capture Detection (GC-ECD) techniques are commonly used for halogenated PGIs/GIs to enhance sensitivity and selectivity. Occasionally, some spectroscopic techniques like Nuclear Magnetic Resonance (NMR), light scattering, and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) are used in analyzing PGIs/GIs.

Track 24: Biologics and Biosimilars

A biopharmaceutical, otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood, or blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant restorative protein, and living cells utilized as a part of cell treatment. Biologics can be made out of sugars, proteins, or nucleic acids or complex mixes of these substances, or might live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some administrative offices utilize the terms natural restorative items or remedial organic item to allude particularly to designed macromolecular items like protein-and nucleic acid–based drugs, recognizing them from items like blood, blood segments, or antibodies, which are typically extricated specifically from a natural source Gene-based and cell biologics, for instance, frequently are at the front line of biomedical research, and might be utilized to treat an assortment of therapeutic conditions for which no different medications are accessible.

Track 25: Pharmaceutical Packaging and Marketing

Packaging is one of the largest industry sectors in the world, worth several billions. There are three major types of pharmaceutical packaging, which are: solid packaging, semi-solids packaging and liquid packaging. The pharmaceutical packaging is a very profitable industry and it is estimated that for 2022 it will reach USD. 8.24 billion. Pharmaceutical packaging represents a meagre percentage of this colossal market. The Global Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. By 2020, pharma cold-chain logistics will be worth $16.7 billion, and non-cold chain at $77.1 billion. The market was estimated at $14.84bn in 2016 and is expected to grow to $28.75bn in 2027.

Track 26: Generic drugs, generic pills and generic medication

A nonexclusive medication (nonspecific medications, short: generics prescriptions) is a medication characterized as "a medication item that is tantamount to a brand/reference recorded medication item in measurements frame, quality, quality and execution attributes, and planned utilize." It has likewise been characterized as a term alluding to any medications showcased under its concoction name without publicizing or to the compound cosmetics of a generic medication as opposed to the promoted mark name under which the medication is sold. Despite the fact that they may not be connected with a specific organization, nonspecific medications are liable to the directions of the administrations of nations where they are apportioned. Worldwide nonspecific is marked with the name of the maker and the received name (non-restrictive name) of the medication. A nonspecific medication and OTC Drugs must contain indistinguishable dynamic fixings from the first definition.

Generic drugs are important options that allow greater access to health care for all Americans. They are copies of brand-name drugs and are the same as those brand name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Health care professionals and consumers can be assured that FDA approved generic drug products have met the same rigid standards as the innovator drug. All generic drugs approved by FDA have the same high quality, strength, purity and stability as brand-name drugs. And, the generic manufacturing, packaging, and testing sites must pass the same quality standards as those of brand name drugs.

Track 27: Tissue Engineering and Regenerative Medicine

Tissue Engineering is a scientific field and also characterized as understanding the standards of tissue and its development by practical trade of deficient tissue for clinical utilize. Tissue building deals about the study of combination of cells, designing, materials strategies, physicochemical and biochemical components to replace or enhance natural tissues. Tissue Engineering involves the use of Scaffolds to form functional tissues and organs, which can be implanted back into the donor host with the use of many engineering and materials methods along with some physicochemical factors. It is related to more than one branch which applies engineering knowledge and life science concepts towards the development of biological substitutes which can improve or restore physiological characteristics of organ.

Regenerative Medicine is branch of translational research in tissue designing which manages the way toward supplanting, building or recovering human cells, tissues or organs to reestablish or set up typical capacity. It is a diversion changing range of prescription with the possibility to completely mend harmed tissues and organs, offering arrangements and seek after individuals who have conditions that today are destroyed. The instruments used to understand these results are tissue building, cell treatments, and restorative gadgets and manufactured organs.

Track 28: Transdermal and Intradermal Drug Delivery Systems

Transdermal Drug Delivery system is an integral part of novel drug delivery system.Drugs having long pharmacokinetic half-lives are considered to be Unsuitable for transdermal application. By the increased number of marketing authorization applications together with recent scientific developments for transdermal patches, the need for clear guidance on specific requirements for this dosage form increased.

The emergence of technological innovations in transdermal patches is expected to provide the market with lucrative growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.

Track 29: Pharmaceutical Technology

Pharmaceutical technology is the piece of equipment of scientific knowledge or technology to pharmacy, pharmacology, and the pharmaceutical industry. It excludes design, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and accumulating of narcotic and other preparations used in diagnostic and determinative procedures and in the treatment of patients.

Track 30: Pharmacotherapy Effect on drug delivery systems

Pharmacotherapy can be characterized as the treatment and counteractive action of ailment and ailment by methods for medications of the synthetic or organic root. It positions among essential techniques for therapeutic treatment, together with surgery, physical therapy, radiation, and psychotherapy. Although it is practically difficult to appraise the correct degree of the effect of pharmacotherapy on human well-being, there can be almost certain that pharmacotherapy, together with enhanced sanitation, better-eating regimen, and better lodging, has improved individuals. Phenomenal advancements in genomics and atomic science today offer a plenty of new medication targets. The utilization of present-day concoction manufactured strategies empowers the blend of many medication hopefuls in shorter circumstances than at any other time.

Track 31: Routes of Drug Administration

The route of administration is the path through which the dosage form (active substance) is administered into the body for treatment of various diseases and disorders. Routes of administration are classified based on 1.the location at which the dosage form is applied 2. Target of action. These include oral, topical and enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Taking them correctly and understanding the right way to administer can reduce the risks. The route used to administer a drug depends on three main factors: 1. the part of the body being treated 2.the way the drug works within the body 3.the formula of the drug. These routes enhance the bio availability of drug molecule.

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market analysis is based on route of administration, facility of use.



Market Analysis

The pharmaceutical industry comprises of companies that are engaged in research, development, manufacture and distribution drugs for human or veterinary use. The primary function of the research-based pharmaceutical corporations is to create value by discovering and producing effective medicines, vaccines and services that improve patients’ well-being, and can be sold in markets at a profit. As well as increasing shareholder value, this contributes significantly to the quality and protection of life and helps make the world a better place. In the past 60 years, innovation and technology have driven huge improvements in global health.

The pharmaceutical industry is undergoing a tremendous deal of change. There are many pharmaceutical companies, who are providing the better products. The Pharma industry is one of the most sought after, and flourished industries. As the pharmaceutical drug manufacturers are one of the reasons for the economic well being of a nation. On the other hand, we can say that the Pharma industry is responsible for the economic development. That is the main reason for both research and development of newer and better products for various kinds of diseases.

Market Analysis of Global Pharmaceutical Industries:

The global $1.12 trillion market in 2022, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.

The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.

The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.

The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval.15 U.S generic drug sales reached an estimated $70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and monetary crisis.

According to the Quintiles IMS Institute predicts that the pharmaceutical market by 2021 will reach nearly USD 1,485 billion, by an increase of USD 350-380 billion from the USD 1,105 billion recorded in 2016. Global brand spending is forecast to increase to USD 815-832 billion in 2021. Global generic spending is expected to increase to USD 495-505 billion by 2021.

The United States share of global spending will increase from USD 461.7 billion in 2016 to USD 645-675 billion in 2021, while the European share of spending will grow from USD 151.8 billion to USD 170-200 billion. Meanwhile, pharmerging countries will spend nearly 315-345 USD billion in 2021 from 242.9 in 2016.

Market Analysis

European pharmaceutical market is set to develop from 169 billion euros in 2015 to 206 billion euros ($229.5 billion) in 2022, showing a compound yearly development rate of 3.25 over the period.

As per another report from life science showcase insight organization Evaluate, development is to a great extent because of developments in oncology, in spite of the fact that progression change propels are additionally rising crosswise over other treatment zones including different sclerosis, constant heart disappointment, rheumatoid joint pain and Alzheimer's. The report is the first to investigate the European medication market to 2022, in view of agreement sedate estimates, using information from Evaluate's recently propelled "European Drug Forecasts" module.

"New advancements, prompting fundamentally enhanced patient results, accompany higher medication costs, doctor's eagerness to endorse, and, in this way, higher agreement tranquilize gauges," said Antonio Iervolino, Evaluate's head of determining.

"In a framework, eventually paid for by governments, this brings up issues on the manageability of the present financing model and introduces challenges for payers inEurope. To lessen the grating amongst payers and industry, another collective way to deal with financing should be set up, at last mirroring the advantages that a portion of the new developments are creating all through the entire medicinal services esteem chain."

Glance at Market of Pharma:

These data describe the outcome of the patient as defined in U.S reporting regulations. Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life threatening. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacy.







Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!